Welcome to our dedicated page for bioAffinity Tech SEC filings (Ticker: BIAF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The bioAffinity Technologies, Inc. (BIAF) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq Capital Market issuer, bioAffinity Technologies files current reports, proxy statements, registration statements and financial reports that describe its biotechnology business focused on noninvasive diagnostics and early detection of lung cancer and other lung diseases.
Through its filings, investors can review Form 8-K current reports detailing material events such as College of American Pathologists (CAP) accreditation for its subsidiary Precision Pathology Laboratory Services, notifications of allowance for U.S. and international patents protecting the CyPath® Lung platform, presentations at major medical conferences and capital-raising transactions, including registered direct offerings under an effective Form S-3 shelf registration statement. These 8-Ks also summarize developments related to Nasdaq listing compliance and monitoring.
Definitive proxy statements filed on Schedule 14A outline governance and capital structure proposals, such as warrant exercise and anti-dilution provisions, preferred stock terms, amendments to equity incentive plans and potential non-public offerings under Nasdaq rules. Together with periodic reports, these documents help explain how bioAffinity Technologies manages its equity, financing options and incentive programs while advancing CyPath® Lung and its diagnostic platform.
On Stock Titan, AI-powered tools can assist in reviewing lengthy filings by highlighting key sections related to revenue sources, laboratory operations, patent portfolio, Nasdaq compliance and financing terms. Users can quickly locate disclosures about the marketing of CyPath® Lung as a Laboratory Developed Test through Precision Pathology Laboratory Services, CAP and CLIA credentials, and the scope of the company’s global patent estate. Real-time EDGAR updates ensure that new BIAF filings, including future 10-K annual reports, 10-Q quarterly reports, 8-K current reports and proxy materials, are surfaced promptly, while AI summaries help interpret complex legal and financial language.
bioAffinity Technologies announced it has regained compliance with Nasdaq listing standards. A Nasdaq Hearings Panel found the company in compliance with Listing Rule 5550(a)(2) (the Minimum Bid Price Rule) and 5550(b)(1) (the Minimum Stockholders’ Equity Rule).
The company will be under a mandatory panel monitor for one year. If, during that period, it falls out of compliance with the Minimum Stockholders’ Equity Rule, it will not be granted additional time to regain compliance, though it may request a new hearing before any delisting. The company issued a press release on October 15, 2025, noting the compliance status.
bioAffinity Technologies entered into a securities purchase agreement with institutional investors for a registered direct offering of 720,000 shares of common stock. The transaction closed on October 9, 2025, providing the company with approximately
WallachBeth Capital, LLC acted as exclusive placement agent and will receive a cash fee of
bioAffinity Technologies, Inc. filed a prospectus supplement describing a common stock offering at an offering price of
bioAffinity Technologies is calling a special stockholder meeting on November 11, 2025 to approve several capital-related proposals. The company seeks authorization to issue up to 271,500 shares of common stock upon exercise of August 2025 warrants, which could provide up to approximately $2.9 million in gross proceeds if exercised for cash.
Stockholders are also asked to approve anti-dilution adjustments that could increase warrant exercise shares up to 365,620 and Series B Preferred conversion shares up to 131,884 following future lower-priced financings. Another proposal would expand the 2024 Equity Incentive Plan reserve from 66,666 to 750,000 shares, a level the board believes is needed for competitive employee and director compensation. The board recommends voting FOR all five proposals, including an adjournment authorization, and notes there were 3,633,815 common shares outstanding as of the October 3, 2025 record date.
bioAffinity Technologies, Inc. reported that sales of its CyPath® Lung diagnostic test for lung cancer reached a new high in the third quarter of 2025. The company disclosed this business update through a press release, which is furnished as an exhibit to this report.
The filing does not include detailed financial figures, but highlights growing adoption of the CyPath® Lung test as a notable operating milestone for the period.
bioAffinity Technologies, Inc. (BIAF) prospectus excerpts show a public offering priced at $2.50 per share with placement agent fees of $0.20 per share, producing proceeds before expenses of $2.30 per share and aggregate proceeds of $4,414,421.31. Historical net tangible book value per share was $0.20; the pro forma increase attributable to the offering is $0.99, producing a pro forma as-adjusted net tangible book value per share of $1.19. The filing notes Total capitalization of $(2,136,108) and references shares issuable upon conversion of 715.5 Series B Convertible Preferred shares at an initial conversion price of $6.90 per share.
Roberto Rios, a director of bioAffinity Technologies, Inc. (BIAF), filed an initial Form 3 disclosing beneficial ownership of 833 shares of the company's common stock. The event requiring the statement occurred on 08/12/2025 and the Form 3 bears a signature date of 09/25/2025. The filing indicates direct ownership and does not disclose any derivative securities or indirect holdings.
bioAffinity Technologies (BIAF) Form 3 — initial ownership disclosure. John J. Oppenheimer, listed as a Director, filed an initial Form 3 reporting that no securities are beneficially owned by him as of the event date 08/12/2025. The form shows the reporting relationship, the issuer symbol BIAF, and a signature dated 09/25/2025.
bioAffinity Technologies, Inc. is registering a primary offering of up to 729,927 shares of common stock, up to 729,927 pre-funded warrants, placement agent warrants for up to 21,898 shares, and up to 751,825 shares underlying these warrants. The company estimates net proceeds of about $3.4 million, assuming $4.0 million in gross sales at an assumed price of $5.48 per share. Shares outstanding would increase from 1,375,102 to 2,105,029 if all common shares (and no pre-funded warrants) are sold. The best-efforts offering has no minimum, so proceeds may be significantly lower, and there is no escrow. The company recently completed a 1-for-30 reverse stock split and is working to regain Nasdaq compliance on minimum bid price and stockholders’ equity.
bioAffinity Technologies, Inc. filed an S-1 registration disclosing an assumed public offering price of $5.48 per share and pro forma capital impacts tied to that offering. The company reported a historical net tangible book value per share of $(1.30) as of June 30, 2025. Pro forma adjustments related to the offering increase net tangible book value by $2.06 to a pro forma as adjusted net tangible book value per share of $0.76. The filing shows a reported dilution to new investors of $4.72 per share. Additional disclosed items include conversion mechanics for Series B Convertible Preferred Stock (conversion price noted as $6.90 per share) and line items for additional paid-in capital and total capitalization figures included in the filing tables.